Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
MEI Pharma
MEI Pharma
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Therapeutic: anticancer agent zandelisib
Phosphatidylinositol 3-kinase delta (PI3K[delta]) is commonly overexpressed in cancer cells. In particular, it plays a vital role in the proliferation and survival of haematologic cancers
Regulatory
Orphan drug designation for AML treatment
Helsinn Group and MEI Pharma announced that Pracinostat has received orphan drug designation from the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML)
Research & Development
Helsinn Group and MEI Pharma to develop acute myeloid leukaemia treatment
MEI Pharma to receive $20m, plus up to $444m in potential milestone payments as well as sales royalties
Subscribe now